Claims for Patent: 7,691,377

Summary for Patent: 7,691,377

Title:	Methods and compositions for treating melanoma
Abstract:	A method for inhibiting melanoma cell growth in a patient by administering to the patient a therapeutically effective amount of a glutamate release inhibitor, a GRM1 antagonist, or a combination thereof
Inventor(s):	Goydos; James S. (East Brunswick, NJ), Chen; Suzie (Highland Park, NJ)
Assignee:	Rutgers, The State University of New Jersey (New Brunswick, NJ)
Application Number:	11/855,890
Patent Claims:	1. A method of inhibiting melanoma cell growth in a patient diagnosed with a melanoma tumor expressing GRM1 comprising administering to said patient an amount of a glutamate release inhibitor, a GRM1 antagonist, or a combination thereof, that is effective to decrease the metabolic activity of said tumor thereby inhibiting melanoma cell growth. 2. The method of claim 1, wherein said GRM1 antagonist is a competitive or noncompetitive GRM1 antagonist. 3. The method of claim 1, wherein said glutamate release inhibitor is 2-amino-6-trifluoromethoxybenzothiazole (riluzole). 4. The method of claim 1, further comprising administering to said patient an anti-proliferative agent, a chemotherapeutic agent, a B-raf inhibitor, a PI3K inhibitor, an antiapoptosis inhibitor, a benzoquinone ansamycin antibiotic, an antiangiogenesis agent, or a combination thereof. 5. The method of claim 4, wherein said chemotherapeutic agent is selected from the group consisting of 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide (temozolomide); 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (dacarbazine); platinum, diammine [1,1-cyclobutane-dicarboxylato (2-)-[0,0']-(SP-4-2) (carboplatin); and 5.beta.,20-Epoxy-1,2.alpha.,4,7.beta.,10.beta.,13.alpha.-hexahydroxytax-1- 1-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (paclitaxel). 6. The method of claim 4, wherein said B-raf inhibitor is 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyri- dine-2-carboxamide 4-methylbenzenesulfonate (sorafenib). 7. The method of claim 4, wherein said antiapoptosis inhibitor is a Bcl-2 inhibitor. 8. The method of claim 4, wherein said benzoquinone ansamycin antibiotic is geldanamycin or 17-N-allylamino-17-demethoxygeldanamycin. 9. The method of claim 4, wherein said antiangiogenesis agent is bevacizumab. 10. The method of claim 1, wherein said glutamate release inhibitor or GRM1 antagonist is administered prior to surgical excision of at least a portion of the melanoma. 11. The method of claim 1, wherein said glutamate release inhibitor or GRM1 antagonist is administered following surgical excision of at least a portion of the melanoma. 12. The method of claim 1, wherein said glutamate release inhibitor or GRM1 antagonist is administered in a chronic dose. 13. The method of claim 1, wherein said glutamate release inhibitor or GRM1 antagonist is administered orally, intravenously, or intraperitoneally.

Details for Patent 7,691,377

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2024-04-16